2011 January 27
Sanofi-aventis Reports Top-line Results from Phase III Study with BSI-201 in Metastatic Triple-Negative Breast Cancer
2011 January 05
Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine
2009 December 11
New Executive Leadership and CEO Announced for BiPar Sciences
2009 December 11
BiPar Sciences Announces Update on the Clinical Development Progress of BSI-201 for Metastatic Triple-Negative Breast Cancer
2009 July 17
BSI-201 Enters Phase 3 in Metastatic Triple Negative Breast Cancer
2009 May 31
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
2009 May 18
BiPar Sciences` Investigational PARP Inhibitor, BSI-201, To Be Highlighted During ASCO`s Plenary Session
2009 April 15
Sanofi-aventis To Acquire BiPar Sciences
2009 February 03
BiPar Sciences to Present At the 11th Annual BIO CEO & Investor Conference in New York City
2009 January 12
BiPar Sciences Raises $20 Million to Advance Clinical Programs
2009 January 07
BiPar Sciences to Present at the 27th Annual JP Morgan Healthcare Conference in San Francisco
2008 December 12
BiPar Sciences Presents Interim Phase 2 Results For PARP Inhibitor BSI-201 at San Antonio Breast Cancer Symposium
2008 December 10
BiPar Sciences Receives 2008 Emerging Technology Award in Biotechnology
2008 December 04
BiPar Sciences to Present at the 31st CTRC-AACR Annual San Antonio Breast Cancer Symposium
2008 October 28
BiPar Sciences' Lead Compound Selected as Top 10 Oncology Drug Candidate
2008 October 21
BiPar to Present at the 7th Annual BIO Investor Forum in San Francisco
2008 September 23
BiPar Sciences Announces Senior Appointments in Corporate Development and Legal Functions
2008 June 02
BiPar Sciences Presents Initial Clinical Data of BSI-201, a Novel DNA Repair Inhibitor
2008 May 28
BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, with Phase 2 Trial in Uterine Cancer
2008 May 15
BiPar Sciences Announces Clinical Data on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
2008 May 08
BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
2008 April 14
BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
2008 April 10
BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2008 February 14
BiPar names Hoyoung Huh, M.D., PH.D., President and Chief Executive Officer
2007 November 15
BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
2007 October 25
BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP1 Gene in Multiple Cancer Types
2007 October 24
BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity with BSI-401, its Second-Generation PARP Inhibitor
2007 October 22
BiPar Announces Upcoming Data Presentations Demonstrating Progress on PARP Inhibitor Drug Pipeline for Cancer
2007 September 25
BiPar Expands Management Team To Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials For Cancer
2007 September 19
BiPar Names G. Kirk Raab Acting Chief Executive Officer
2007 May 17
BiPar Names John Schembri Chief Financial Officer
2007 February 26
BiPar Sciences Raises $35 Million to Advance Pipeline of Novel PARP Inhibitor Cancer Drug Candidates
2007 January 04
BiPar Sciences Begins Enrollment in Phase 1b Study of BSI-201
2006 August 07
BiPar Sciences Co-Founder Allan Basbaum Honored with Membership in Royal Society
2006 June 14
BiPar Sciences Announces $5 Million Financing to Accelerate BSI-201 Clinical Program
2006 March 07
BiPar Sciences Announces Start of Phase 1 Clinical Trial for BSI-201 in Patients With Advanced Cancer; Lead Product Candidate in Clinic Just One Year After Initial Financing Round
2004 December 20
BiPar Sciences Raises $13 Million in Series A Financing
